


Rena Therapeutics

Target : Rena Therapeutics Inc.

Outline : R&D of nucleic acid medicine platform technologies based on Hetero-Duplex Oligonucleotide Technology

Authorized investment : ¥600 million (maximum) / ¥300 million* (maximum)

* multiple investments will be made on a milestone basis



- Support a biotech company to commercialize a platform technology to strengthen nucleic acid therapeutics research in Japan
- Maximize value of intellectual properties generated at academia in Japan
- Contribute to facilitate developments of any nucleic acid therapeutics in pipelines at any third parties